ACADIA Pharmaceuticals (ACAD) Income Statement
ACADIA Pharmaceuticals Income Statement
Last quarter (Q2 2026), ACADIA Pharmaceuticals's total revenue was $307.96M, an increase of 16.40% from the same quarter last year. In Q2, ACADIA Pharmaceuticals's net income was $31.50M. See ACADIA Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 1.07B | $ 957.80M | $ 726.44M | $ 517.24M | $ 484.14M | |
| $ 982.51M | $ 875.96M | $ 680.71M | $ 507.07M | $ 465.00M | |
| $ 877.70M | $ 645.16M | $ 754.09M | $ 730.66M | $ 635.44M | |
| Depreciation and Amortization | $ 11.76M | $ 15.88M | $ 5.55M | $ 2.03M | $ 3.34M |
| $ 150.66M | $ 100.16M | $ -45.48M | $ -211.42M | $ -164.18M | |
| $ 104.81M | $ 230.79M | $ -73.38M | $ -223.60M | $ -170.44M | |
| $ 34.09M | $ 27.28M | $ 22.34M | $ 10.15M | $ 2.92M | |
| $ 138.90M | $ 258.07M | $ -51.04M | $ -213.44M | $ -167.52M | |
| $ 391.00M | $ 226.45M | $ -61.29M | $ -215.97M | $ -167.87M | |
| Per Share Metrics | |||||
| Basic EPS | $ 2.32 | $ 1.37 | $ -0.37 | $ -1.34 | $ -1.05 |
| Diluted EPS | $ 2.29 | $ 1.36 | $ -0.37 | $ -1.34 | $ -1.05 |
| Weighted Average Shares Outstanding | 169.34M | 165.72M | 163.82M | 161.68M | 160.49M |
| Weighted Average Shares Outstanding (Diluted) | 171.36M | 166.36M | 163.82M | 161.68M | 160.49M |
Currency in USD
